Table 4.
Clinical assessment values upon enrollment (baseline) and after 1 year of follow-up.
| Baseline | 1 year | p value | |
|---|---|---|---|
| mH&Y score | 2.5 ± 0.6 | 2.5 ± 0.7 | 0.7 |
| UPDRS I | 2.2 ± 1.6 | 2.4 ± 1.7 | 0.7 |
| UPDRS II | 8.6 ± 6.0 | 6.7 ± 3.9 | 0.3 |
| UPDRS III | 14.2 ± 9.4 | 16.5 ± 9.9 | 0.4 |
| UPDRS IV | 2.4 ± 2.8 | 2.2 ± 2.1 | 0.7 |
| UPDRS total | 27.3 ± 13.7 | 27.8 ± 13.8 | 0.9 |
| MMSE | 28.3 ± 1.7 | 26.9 ± 2.3 | 0.008 |
| FFT angle (°) | 12.8 ± 12.9 | 13.9 ± 9.8 | 0.6 |
| SV angle (°) | 6.0 ± 9.8 | 11.0 ± 6.1 | 0.02 |
| LED (mg/day) | 636 ± 199.4 | 939 ± 368.4 | 0.001 |
| Dopamine agonist (%) | 100 | 94.4 | 0.5 |
Mean ± SD values are shown. mH&Y Scale, modified Hoehn & Yahr Scale; MMSE, Mini-Mental State Examination; FFT angle, forward flexion of trunk angle; SV angle, subjective vertical position angle; UPDRS, Unified Parkinson's Disease Rating Scale; LED, levodopa-equivalent dose.